Rokote Laboratories signs an agreement with 3PBIOVIAN for GMP manufacturing of adenovirus vector-based COVID-19 vaccineAugust 29, 2024Read more >
Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN, a leading pan-European biologics CDMOFebruary 1, 2024Read more >
3P Biopharmaceuticals: building a legacy of innovation and excellence in biotechnologyDecember 20, 2023Read more >
Biovian announces the successful refinancing of its existing debt package and the securing of new funding to support GeneCity facility expansion December 18, 2023Read more >
3P Biopharmaceuticals and the University of Navarra bring the Neanderthal world and biomedicine to the public in a successful event.October 19, 2023Read more >
3P Biopharmecuiticals celebrates cerebral palsy day in collaboration with ASPACEOctober 6, 2023Read more >
3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis.September 19, 2023Read more >
Biovian announces over €50 million investment in manufacturing facility in Turku, FinlandJuly 26, 2023Read more >